Resistance to anti-influenza drugs: Adamantanes and neuraminidase inhibitors

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 795-805

  Hurt, Aeron C ^a   Ho, Hui Ting ^a   Barr, Ian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Adamantanes; Amantadine; Drug resistance; Influenza; Neuraminidase inhibitors; Oseltamivir; Relenza ; Rimantadine; Tamiflu ; Zanamivir

Indexed keywords

A 315675; ADAMANTANE DERIVATIVE; ANTIVIRUS AGENT; HEMAGGLUTININ; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR; T 705; ZANAMIVIR;

BRONCHOSPASM; BRONCHUS DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG TREATMENT FAILURE; EPIDEMIC; FOOD; GENE MUTATION; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; VIRUS RESISTANCE; VOMITING;

EID: 33845384187     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.5.795     Document Type: Review

References (89)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76(1), 105-115 (2002).
2. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis. 11(9), 1355-1362 (2005).
3. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Public Health. 87(12), 1944-1950 (1997).
4. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21(16), 1769-1775 (2003).
5. Wiselka M. Influenza: diagnosis, management, and prophylaxis. Br. Med. J. 308(6940), 1341-1345 (1994).
6. Wood JM. Developing vaccines against pandemic influenza. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356(1416), 1953-1960 (2001).
7. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. (2006).
8. Davies WL, Grunert RR, Haff RF et al. Antiviral activity of 1-adamantanamine (amantadine). Science 144, 862-863 (1964).
9. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 53(RR-6), 1-40 (2004).
10. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4(11), 3021-3024 (1985).
11. Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 281(14), 8997-9000 (2006).
12. Cox NJ, Subbarao K. Influenza. Lancet 354(9186), 1277-1282 (1999).
13. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and amantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother 23(3), 458-464 (1983).
14. Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob. Agents Chemother. 28(2), 216-221 (1985).
15. Hayden FG. Antiviral resistance in influenza viruses - implications for management and pandemic response. N. Engl. J. Med. 354(8), 785-788 (2006).
16. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14(3), 327-332 (1992).
17. von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418-423 (1993).
18. Meindl P, Tuppy H. 2-deoxy-2,3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids. Hoppe Seylers Z. Physiol. Chem. 350(9), 1088-1092 (1969).
19. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353(13), 1363-1373 (2005).
20. Murphy KR, Eivindson A, Stein WJ et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin. Drug Invest. 20(5), 337-345 (2000).
21. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37(6), 471-484 (1999).
22. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother. 49(2), 556-559 (2005).
23. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62(5), 1508-1512 (1988).
24. Saito R, Sakai T, Sato I et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2, J. Clin. Microbiol. 41(5), 2164-2165 (2003).
25. Schmidtke M, Zell R, Bauer K et al. Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 49(5), 286-293 (2006).
26. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob. Agents Chemother. 35(9), 1741-1747 (1991).
27. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 188(1), 57-61 (2003).
28. Ziegler T, Hemphill ML, Ziegler ML et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis. 180(4), 935-939 (1999).
29. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005).
30. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295(8), 891-894 (2006).
31. Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res. (2006) (In press).
32. Miller J, Schmit K, Duncan P et al. Increased antiviral medication sales before the 2005-06 influenza season - New York City. MMWR Morb. Mortal. Wkly Rep. 55(10), 277-279 (2006).
33. Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J. Clin. Microbiol. 40(1), 84-88 (2002).
34. Schilling M, Gravenstein S, Drinka P et al. Emergence and transmission of amantadine-resistant influenza A in a nursing home. J. Am. Geriatr. Soc. 52(12), 2069-2073 (2004).
35. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67(6), 2972-2980 (1993).
36. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 47(1), 1-17 (2000).
37. Barnett JM, Cadman A, Burrell FM et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 265(2), 286-295 (1999).
38. Blick TJ, Sahasrabudhe A, McDonald M et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246(1), 95-103 (1998).
39. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70(3), 1818-1827 (1996).
40. Convington E, Mendel D B, Escarpe PA, Tai CY, Soderbarg K, Roberts NA. Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir. J. Clin. Virol. 18, P-326 (2000).
41. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183(4), 523-531 (2001).
42. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001).
43. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436), 759-765 (2004).
44. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1), i5-i21 (2005).
45. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178(5), 1257-1262 (1998).
46. Gubareva LV. Characterization of influenza A and B viruses recovered from immunocompromised patients treated with antivirals. Int. Congr. Ser. 1263, 126-129 (2004).
47. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193(6), 760-764 (2006).
48. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348(9), 867-868 (2003).
49. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103(1-2), 199-203 (2004).
50. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49(3), 147-156 (2001).
51. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47(7), 2264-2272 (2003).
52. Hurt AC, Barr IG, Durrant CJ, Shaw RP, Sjogren HM, Hampson AW. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun. Dis. Intell. 27(4), 542-547 (2003).
53. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62(1), 37-45 (2004).
54. Sugaya N. Anti-virals for influenza virus infection. Uirusu 55(1), 111-114 (2005).
55. Hurt AC, Iannello P, Jachno K et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 50(5), 1872-1874 (2006).
56. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71(5), 3385-3390 (1997).
57. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72(3), 2456-2462 (1998).
58. Tai CY, Escarpe PA, Sidwell RW et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42(12), 3234-3241 (1998).
59. Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49(10), 4075-4084 (2005).
60. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54(2), 79-88 (2002).
61. Herlocher ML, Carr J, Ives J et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54(2), 99-111 (2002).
62. Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neraminidase inhibitor resistance. Wkly Epidemiol. Rec. 80(17), 156 (2005).
63. Blick TJ, Tiong T, Sahasrabudhe A et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214(2), 475-484 (1995).
64. Colacino JM, Chirgadze NY, Garman E et al. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236(1), 66-75 (1997).
65. McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225(1), 240-242 (1996).
66. Ives J, Carr J, Roberts NA et al. An oseltamivir treatment-selected influenza A/Wuhan/359/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo. J. Clin. Virol. 18, 251-269 (2000).
67. Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190(9), 1627-1630 (2004).
68. Gubareva LV, Tai CY, Mendel DB et al. Oseltamivir treatment of experimental influenza A/Texas/36/91 (H1N1) virus infection in humans: selection of a novel neuraminidase variant. Antiviral Res. 46, A54 (2000).
69. Wang ZM, Tai CY, Mendel DB. Characterization of an influenza A virus variant selected in vitro in the presence of the neruaminidase inhibitor, GS4071. Antiviral Res. 46, A60 (2000).
70. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother 46(12), 3809-3816 (2002).
71. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/ H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55(2), 307-317 (2002).
72. Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41(2), 742-750 (2003).
73. Jackson D, Barclay W, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55(2), 162-169 (2005).
74. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40(1), 40-46 (1996).
75. Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363(9409), 617-619 (2004).
76. Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193(12), 1626-1629 (2006).
77. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45(10), 2723-2732 (2001).
78. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005).
79. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005).
80. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 70(3), 121-131 (2006).
81. Kati WM, Montgomery D, Carrick R et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46(4), 1014-1021 (2002).
82. Macdonald SJ, Cameron R, Demaine DA et al. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem. 48(8), 2964-2971 (2005).
83. Sidwell RW, Smee DF. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin. Investig. Drugs. 11(6), 859-869 (2002).
84. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49(11), 4515-4520 (2005).
85. Shigeta S, Mori S, Watanabe J, Soeda S, Takahashi K, Yamase T. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob. Agents Chemother. 41(7), 1423-1427 (1997).
86. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl Acad. Sci. USA 101(23), 8676-8681 (2004).
87. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49(3), 981-986 (2005).
88. Staschke KA, Colacino JM, Baxter AJ et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214(2), 642-646 (1995).
89. Carr J, Ives J, Roberts N et al. Virological assessment in vitro and in vivo of an influenza H1N1 virus with a H274Y mutation in the neuraminidase gene. Antiviral Res. 46, A59 (2000).